Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Xwpharma Ltd. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across distinct art units and involve distinct examiners. ZOHREH ALEMZADEH FAY is the busiest examiner with 1 pending action, indicating that the workload is split between the assigned individuals. This structure requires monitoring separate art units for potential prosecution developments.
With the 2 pending office actions, the company must maintain a strategy to address the specific requirements of the Biotechnology & Pharmaceuticals sector. The involvement of the distinct art units suggests that the patent applications cover different technical aspects or chemical compositions. Because ZOHREH ALEMZADEH FAY and the other examiner each handle 1 pending action, the company can compare the responsiveness and rigor of different examiners. This balanced distribution allows for a diversified approach to securing patent protection without over-reliance on a single USPTO official.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FAY, ZOHREH ALEMZADEH | 1 | 52.2% | -6.2% |
| CHANG, KYUNG SOOK | 1 | 60.4% | +40.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18789859 | EXCIPIENT GRANULATIONS | FAY, ZOHREH ALEMZADEH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17737700 | PHARMACEUTICAL GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | CHANG, KYUNG SOOK | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18789859 | EXCIPIENT GRANULATIONS | FAY, ZOHREH ALEMZADEH | 1617 | §102§103 | Non-Final OA | — | Pending | Jul 31, 2024 |
| 17737700 | PHARMACEUTICAL GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | CHANG, KYUNG SOOK | 1613 | §103 | Non-Final OA | — | Pending | May 05, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial